Two cases of systemic mastocytosis with RUNX1-RUNX1T1 positive acute myeloid leukemia treated with sequential avapritinib after allogeneic hematopoietic stem cell transplantation and literature review

Systemic mastocytosis (SM) with RUNX1-RUNX1T1 positive acute myeloid leukemia (AML) is a rare myeloid tumor with no standard treatment. Two cases of SM patients with RUNX1-RUNX1T1 positive AML treated with sequential avapritinib after allogeneic hematopoietic stem cell transplantation (allo-HSCT) we...

Full description

Saved in:
Bibliographic Details
Published in:Zhōnghuá xuèyèxué zázhì 2024-05, Vol.45 (5), p.505
Main Authors: Wang, J, Zu, Y L, Gui, R R, Li, Z, Zhang, Yanli, Zhou, J
Format: Article
Language:Chinese
Subjects:
Adult
Core Binding Factor Alpha 2 Subunit - genetics
Female
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - therapy
Male
Mastocytosis, Systemic - genetics
Mastocytosis, Systemic - therapy
Middle Aged
Oncogene Proteins, Fusion - genetics
Pyrazines - administration & dosage
Pyrazoles
Pyrroles
RUNX1 Translocation Partner 1 Protein - genetics
Transplantation, Homologous
Triazines
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systemic mastocytosis (SM) with RUNX1-RUNX1T1 positive acute myeloid leukemia (AML) is a rare myeloid tumor with no standard treatment. Two cases of SM patients with RUNX1-RUNX1T1 positive AML treated with sequential avapritinib after allogeneic hematopoietic stem cell transplantation (allo-HSCT) were reported in Henan Cancer Hospital. Mast cell in bone marrow disappeared, C-KIT mutation and RUNX1-RUNX1T1 fusion gene remained negative. Allo-HSCT sequential avapritinib is an effective treatment for SM patients with RUNX1-RUNX1T1 positive AML.
ISSN:0253-2727
DOI:10.3760/cma.j.cn121090-20240313-00092